Nanotherapy Shrinks Artery Plaque in Mouse Study

Plaque coverage fell by more than two-thirds in treated mice, but the therapy has not yet been tested in people.

Updated on Nov. 4, 2026 in Heart Disease

Bold vector editorial illustration of a glass pipette releasing pale droplets over a dark blue field, evoking targeted plaque treatment research.
Researchers reported that a targeted nanotherapy reduced artery plaque by more than two-thirds in mice, though it has not yet been tested in people. AI Illustration. Upload story photo >

Researchers developed a targeted nanoimmunotherapy that reduced atherosclerotic plaque burden in mice. In a 12-week study, the treatment lowered plaque coverage of the aortic area to 9.4% versus 32.4% in saline controls, and the approach remains preclinical.

Why it matters

Atherosclerotic plaques that become unstable are a central driver of heart attacks and strokes, and current approaches largely target risk factors rather than the plaque itself. A therapy that stabilizes plaque directly would be a new kind of prevention strategy if it proves safe and effective in people, though that is not yet established.

This preclinical study tested the nanotherapy in mice with advanced atherosclerosis, comparing treated animals to saline-treated controls over 12 weeks. The treatment reduced plaque coverage of the aortic area from 32.4% in controls to 9.4%, and no obvious toxicity was seen in tissue, blood chemistry, or blood cell measurements under the conditions tested.

The players

Acta Pharmaceutica Sinica B

A peer-reviewed journal that publishes pharmaceutical science research, including drug delivery and nanomedicine studies, and where this nanoimmunotherapy study appeared.

News-Medical

A medical news outlet that reports on health research, including this report on the nanoimmunotherapy study.

The details

The therapy uses phosphorene nanosheets, a thin material with immune-modulating activity, which were modified with a peptide (KC11) that binds collagen IV, a component of plaque tissue, and loaded with Resolvin D1, a molecule that helps resolve inflammation. The resulting formulation, PP@KC/RD, accumulated in plaques and was taken up efficiently by macrophages inside lesions. In cell experiments, it improved efferocytosis, the process by which macrophages clear dying cells, and shifted macrophages toward an M2-like phenotype, with increased MerTK receptor expression and reduced CaMKIIγ signaling linked to better clearance.

Timeline

  1. 12 weeks: duration of the twice-weekly intravenous treatment course in mice

  2. News-Medical published its article on the study on 4 November 2026

Health Landscape

Most current cardiovascular prevention focuses on lowering risk factors such as cholesterol and blood pressure rather than directly altering established plaque. Research into macrophage efferocytosis, the clearance of dying cells that becomes impaired in advanced lesions, offers a mechanistic route toward plaque stabilization that this preclinical work tests with a targeted nanotherapy.

This work is preclinical, so it does not change current care, but it highlights that plaque stability, not just cholesterol level, is an active research target. If you have known heart disease or risk factors, it is worth discussing with your doctor which proven prevention steps apply to you now.

The takeaway

A targeted therapy that stabilizes plaque is a promising research direction, but it has only been tested in mice so far. Anyone managing heart disease risk should keep using proven measures and bring questions about emerging treatments to their physician.

Further reading

For background on the condition at the center of this research, explore our coverage in Heart Disease.

More information

Read the peer-reviewed Acta Pharmaceutica Sinica B article on nanoimmunotherapy for full study details.